Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study
Authors' conclusion
Finerenone treatment was associated with a significant reduction in proteinuria in patients with DKD. The safety profile was comparable to that reported in previous studies.
Study context
- Population
- Patients with diabetic kidney disease (DKD) prescribed finerenone in routine clinical practiceanalysed
- Participants
- 404 patients
- Outcome
- Changes in UPCR and UACR
- Follow-up
- 6 months after finerenone initiation
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
6 months
Urine protein-to-creatinine ratio (UPCR) mean within-subject change (± value as printed), mg/g
−820.2 ± 1528.3
Urine albumin-to-creatinine ratio (UACR) mean within-subject change (± value as printed), mg/g
−606.4 ± 1119.6
Observational data: associations, not effects.
Further findings
≥30% reduction in UPCR from baseline · 6 months
- Patients achieving a ≥30% reduction in UPCR from baseline
- 59.9%
Predictors of response
- Older age, lower baseline potassium and higher mean daily finerenone dose associated with a more favourable response
Aldosterone-to-renin ratio · 3 months
- Modest decrease in aldosterone-to-renin ratio, mean within-subject change (± SD)
- −3.79 ± 13.76 ng/dL per ng/mL/h
- Borderline statistical significance
Safety
Potassium and hyperkalemia · 6 months
- Mean increase in potassium levels
- 0.3 mEq/L
- Treatment discontinuation due to hyperkalemia
- 5.4%
Original publication
Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study. Diabetes Obes Metab. Published 4 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →